ENTITY
Biogen Inc

Biogen Inc (BIIB US)

137
Analysis
Health CareUnited States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
more
Refresh
04 May 2018 22:02

Samsung BioLogics and Biogen: Who Had Control?

The controversy surrounding Samsung Biologics Co., Ltd (207940 KS) 's booking of a fair value gain in 2015 relates to their claim of a "loss of...

Share
12 Apr 2018 23:44

A Conversation with Biogen

Biogen Inc (BIIB US) is Samsung Biologics Co., Ltd (207940 KS) 's minority (5.4%) partner in the Samsung Bioepis JV that manufactures and sells...

Share
bearishBiogen Inc
15 Mar 2018 22:36

Standing Alone in the Ampakines Pipeline: Biogen Sees Potential in Pfizer's Neuropsychiatry Asset

On 12 March 2018, Biogen Inc (BIIB US) announced an agreement to acquire Pfizer Inc (PFE US)'s first-in-class, Phase 2b ready AMPA receptor...

Logo
197 Views
Share
01 Mar 2018 08:44

Will Actinogen Ace Alzheimer's?

Alzheimer’s disease is an incurable neurodegenerative disorder that robs the affected individuals of memory, self-care and quality of life,...

Logo
213 Views
Share
bearishCelltrion Inc
15 Feb 2018 23:24

Biosimilar Battlefield: An Update

Korea's biosimilar plays, Celltrion Inc (068270 KS) , Celltrion Pharm Inc (068760 KS) , Celltrion Healthcare (091990 KS) , and Samsung Biologics...

Share
x